NEW YORK, NY / ACCESSWIRE / April 10, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)
Class Period: August 4, 2016 - January 31, 2019
Lead Plaintiff Deadline : April 26, 2019
Join the action: https://www.zlk.com/pslra-1/aveo-pharmaceuticals-inc-loss-form?prid=1025&wire=1.
Allegations: AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO's lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO's public statements were materially false and misleading at all relevant times.
To learn more about the AVEO Pharmaceuticals, Inc. class action contact jlevi@levikorsinsky.com.
Amarin Corporation (NASDAQGM: AMRN)
Class Period: September 24, 2018 - November 9, 2018
Lead Plaintiff Deadline : April 23, 2019
Join the action: https://www.zlk.com/pslra-1/amarin-corporation-loss-form?prid=1025&wire=1.
Allegations: During the class period, Amarin Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin's public statements were materially false and misleading at all relevant times.
To learn more about the Amarin Corporation class action contact jlevi@levikorsinsky.com.
Syneos Health, Inc. (NASDAQ: SYNH)
Class Period: May 10, 2017 - February 27, 2019
Lead Plaintiff Deadline : April 30, 2019
Join the action: https://www.zlk.com/pslra-1/syneos-health-inc-loss-form?prid=1025&wire=1
Allegations: Syneos Health, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Syneos Health's internal control over financial reporting was inadequate; (2) concerns regarding Syneos Health's internal control over financial reporting would result in heightened regulatory scrutiny and an SEC investigation into the company's revenue accounting policies, internal controls and related matters; and (3) as a result, defendants' statements about Syneos Health's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Syneos Health, Inc. class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/541611/CLASS-ACTION-UPDATE-for-AVEO-AMRN-and-SYNH-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
